OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
TipRanks (Tue, 28-Jul 7:28 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
Globe Newswire (Tue, 28-Jul 7:00 AM ET)
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
TipRanks (Mon, 27-Jul 7:27 AM ET)
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Director
Globe Newswire (Thu, 23-Jul 12:00 PM ET)
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
Globe Newswire (Thu, 23-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
Globe Newswire (Wed, 22-Jul 10:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Globe Newswire (Tue, 21-Jul 9:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chairman
Globe Newswire (Tue, 21-Jul 7:00 AM ET)
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Okyo Pharma Limited - trades on the NASDAQ stock market under the symbol OKYO.
As of July 31, 2026, OKYO stock price climbed to $1.68 with 25,799 million shares trading.
OKYO has a beta of 1.31, meaning it tends to be more sensitive to market movements. OKYO has a correlation of 0.06 to the broad based SPY ETF.
OKYO has a market cap of $88.17 million. This is considered a Micro Cap stock.
In the last 3 years, OKYO traded as high as $3.35 and as low as $.81.
OKYO has underperformed the market in the last year with a return of -33.1%, while SPY returned +18.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OKYO shares. However, OKYO has outperformed the market in the last 3 month and 2 week periods, returning +7.7% and +21.7%, while SPY returned +4.2% and -0.5%, respectively. This indicates OKYO has been having a stronger performance recently.
OKYO support price is $1.57 and resistance is $1.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKYO shares will trade within this expected range on the day.